Author Archives: admin


Lab grown human colons change study of GI disease – Medical Xpress

June 22, 2017 This confocal microscopic image shows a human colon organoid generated in the laboratory with human pluripotent stem cells. The organoid is shown after it was transplanted into a mouse. The engineered colon secreted proteins found in natural human colon. Researchers report study results in Cell Stem Cell. Credit: Cincinnati Children's

Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when transplanted into mice, according to research published June 22 in Cell Stem Cell.

The study is believed to be the first time human colon organoids have been successfully tissue engineered in this manner, according to researchers at Cincinnati Children's Hospital Medical Center who led the project.

The technology allows diseases of the colon to be studied in unprecedented detail in a human modeling system. It also comes with the potential to one day generate human gastrointestinal (GI) tract tissues for transplant into patients, according to James Wells, PhD, senior study investigator and director of the Cincinnati Children's Pluripotent Stem Cell Center.

"Diseases affecting this region of the GI tract are quite prevalent and include ailments like colitis, colon cancer, Irritable Bowel Syndrome, Hirschsprung's disease and polyposis syndromes," Wells said. "We've been limited in how we can study these diseases, including the fact that animal models like mice don't precisely recreate human disease processes in the gastrointestinal tract. This system allows us to very effectively model human diseases and human development."

Building the GI Tract

In a series of studies published since 2009, researchers in Wells' laboratory used human pluripotent stem cells (hPSCs) to grow embryonic-stage small intestines with a functioning nervous system, and the antrum and fundus regions of the human stomach.

The researchers - including Jorge Munera, PhD, first author and postdoctoral fellow in the Wells laboratory - note in their current paper the colon has been more difficult to generate than other parts of the GI tract.

Part of the challenge to identifying the correct genetic and molecular programming to coax hPSCs in to colonic organoids has been a lack of data about embryonic development of the organ, according to the authors. They addressed this by conducting a series of molecular and genetic screens of developing hindgut tissues in animal models. The hindgut is the portion of the developing gut that gives rise to the entire large intestine - which includes the cecum, colon and rectum.

They also mined public databases (GNCPro, TiGER, Human Protein Atlas) to identify molecular markers of the hindgut in the adult colon.

Frogs and Mice at Forefront

To develop a model for generating the human colon, scientists first identified SATB2 (special AT-rich sequence-binding protein 2) as a definitive molecular marker for hindgut in frogs, mice and in humans.

SATB2 is a DNA-binding protein that facilitates structural organization of chromosomes in the nucleus of cells.

The protein sequence of SATB2 is remarkably similar between frogs, mice and humans. This led the authors to the hypothesis that molecular signals regulating SATB2 in frogs and mice could be used to make human colon organoids that express the protein.

The authors also noticed that signaling from the growth factor BMP (bone morphogenetic protein) was highly active in the SATB2-expressing region of the gut tube. The researchers learned during their analysis of frog, mouse and human stem-cell derived intestine that signaling by BMP is needed to establish SATB2 in the developing hindgut. With SABT2 as a marker, the researchers show BMP signaling is required for development of tissues specific to the posterior gut region of frogs and mice where the colon develops.

When BMP protein was added for three days in human pluripotent stem cell-derived gut tube cultures, it induced a posterior HOX code. HOX includes a critical set of genes that help control the embryo's development plan from head to toe. Researchers report the posterior HOX helps control the formation of SATB2-expressing human colon organoids.

Testing Translational Potential

To see how human GI tissues perform in a living organism - and to test their future therapeutic potential - the research team included collaborators from the Division of Surgery, led by Michael Helmrath, MD, a pediatric surgeon and director of the Surgical Research program.

The tissue-engineered colonic organoids were transplanted into the kidney capsules of immunocompromised mice for six to 10 weeks. During observation and analysis of the now in vivo organoids, study authors looked for signs of posterior region enteroendocrine cells, which make hormones found in naturally developed human colon.

Researchers report that following transplant, the human colonic organoids assumed the form, different structures and molecular and cell properties of the human colon.

Munera, study first author, pointed to a number of new ways that human colon organoids could be used study disease.

"By exposing human colonic organoids to inflammatory triggers, we can now learn how the cell lining of the colon and the supporting cells beneath cooperate to respond to inflammation," Munera said. "This could be very relevant for patients with Crohn's disease or ulcerative colitis. And because the microbiome, the organisms that live in our guts, are most concentrated in the colon, the organoids potentially could be used to model the human microbiome in health and disease."

Like other parts of the GI tract grown by the researchers, the human colon organoids also create a potential new platform for testing new drugs before the start of clinical trials. Most oral drugs are absorbed by the body through the gut.

Explore further: Human tissue model developed to test colon cancer drugs

More information: Cell Stem Cell (2017). DOI: 10.1016/j.stem.2017.05.020

New research overturns long-held views on a basic messaging system within living cells. Key cellular communication machinery is more regionally constrained within the cell than previously thought. The findings suggest new ...

The leading cause of acute gastroenteritis linked to eating raw seafood disarms a key host defense system in a novel way: It paralyzes a cell's skeleton, or cytoskeleton.

It's a tiny marine invertebrate, no more than 3 millimeters in size. But closely related to humans, Botryllus schlosseri might hold the key to new treatments for cancer and a host of vascular diseases.

Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when transplanted into mice, according to research published June 22 in Cell Stem ...

Paracetamol is popular for relieving pain. But if you are pregnant, you should think twice before popping these pills according to the researchers in a new study. In an animal model, Paracetamol, which is the pain-relieving ...

Fathers-to-be, take note: You may be more useful in the labor and delivery room than you realize.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See original here:
Lab grown human colons change study of GI disease - Medical Xpress

Localized signaling islands in cells: New targets for precision drug design – Medical Xpress

June 22, 2017

New research overturns long-held views on a basic messaging system within living cells. Key cellular communication machinery is more regionally constrained within the cell than previously thought. The findings suggest new approaches to designing precision drugs. Localizing drug action at a specific 'address' within the cell could mean fewer side effects in treating cancer, diabetes, heart disease and other serious conditions.

Research results reported this week in the journal Science overturn long-held views on a basic messaging system within living cells.

The findings suggest new approaches to designing precisely targeted drugs for cancer and other serious diseases.

Dr. John D. Scott, professor and chair of pharmacology at the University of Washington School of Medicine and a Howard Hughes Medical Institute Investigator, along with Dr. F. Donelson Smith of the UW and HHMI, led this study, which also involved Drs. Claire and Patrick Eyers and their group at the University of Liverpool.

The researchers explained that key cellular communication machinery is more regionally constrained inside the cell than was previously thought. Communication via this vital system is akin to social networking on your Snapchat account.

Within a cell, the precise positioning of such messaging components allows hormones, the body's chief chemical communicators, to transmit information to exact places inside the cell. Accurate and very local activation of the enzyme that Scott and his group study helps assure a correct response occurs in the right place and at the right time.

The video will load shortly

"The inside of a cell is like a crowded city," said Scott, "It is a place of construction and tearing down, goods being transported and trash being recycled, countless messages, (such as the ones we have discovered), assembly lines flowing, and packages moving. Strategically switching on signaling enzyme islands allows these biochemical activities to keep the cell alive and is important to protect against the onset of chronic diseases such as diabetes, heart disease and certain cancers."

Advances in electron microscopy and native mass spectrometry enabled the researchers to determine that a critical component of the signaling system, anchored protein kinase A, remains intact during activation. Parts of the molecule are flexible, allowing it to both contract and stretch, with floppy arms that can reach out to find appropriate targets.

Still, where the molecule performs its act, space is tight. The distance is, in fact, about the width of two proteins inside the cell.

The video will load shortly

"We realize that in designing drugs to reach such targets that they will have to work within very narrow confines, " Scott said.

One of his group's collective goals is figuring out how to deliver precision drugs to the right address within this teeming cytoplasmic metropolis.

"Insulating the signal so that the drug effect can't happen elsewhere in the cell is an equally important aspect of drug development because it could greatly reduce side effects," Scott said.

An effort to take this idea of precision medicine a step further is part of the Institute for Targeted Therapeutics at UW Medicine in Seattle. The institute is being set up by Scott and his colleagues in the UW Department of Pharmacology.

The scientists are collaborating with cancer researchers to better understand the molecular causesand possible future treatmentsfor a certain liver malignancy. This particular liver cancer arises from a mutation that produces an abnormal form of the enzyme that is the topic of this current work, protein kinase A, and alters the enzyme's role in cell signaling.

The video will load shortly

Other advances that gave the researchers a clearer view of the signaling mechanisms reported in Science include CRISPR gene editing, live-cell imaging techniques, and more powerful ways to look at all components of a protein complex.

Explore further: Study unveils T cell signaling process central to immune response

More information: "Local protein kinase A action proceeds through intact holoenzymes" Science (2017). science.sciencemag.org/cgi/doi/10.1126/science.aaj1669

Journal reference: Science

Provided by: University of Washington

New research overturns long-held views on a basic messaging system within living cells. Key cellular communication machinery is more regionally constrained within the cell than previously thought. The findings suggest new ...

The leading cause of acute gastroenteritis linked to eating raw seafood disarms a key host defense system in a novel way: It paralyzes a cell's skeleton, or cytoskeleton.

It's a tiny marine invertebrate, no more than 3 millimeters in size. But closely related to humans, Botryllus schlosseri might hold the key to new treatments for cancer and a host of vascular diseases.

Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when transplanted into mice, according to research published June 22 in Cell Stem ...

Paracetamol is popular for relieving pain. But if you are pregnant, you should think twice before popping these pills according to the researchers in a new study. In an animal model, Paracetamol, which is the pain-relieving ...

Fathers-to-be, take note: You may be more useful in the labor and delivery room than you realize.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Original post:
Localized signaling islands in cells: New targets for precision drug design - Medical Xpress

Cells In Fish’s Spinal Discs Repair Themselves – Duke Today

Duke researchers have discovered a unique repair mechanism in the developing backbone of zebrafish that could give insight into why spinal discs of longer-lived organisms like humans degenerate with age.

The repair mechanism apparently protects the fluid-filled cells of the notochord, the precursor of the spine, from mechanical stress as a young fish begins swimming. Notochord cells go on to form the gelatinous center of intervertebral discs, the flat, round cushions wedged between each vertebrae that act as shock absorbers for the spine.

The disappearance of these cells over time is associated with degenerative disc disease, a major cause of human pain and disability worldwide.

It is not difficult to speculate that these same mechanisms of repair and regeneration are present in humans at very early stages, but are lost over time," said Michel Bagnat, Ph.D., senior author of the study and assistant professor of cell biology at Duke University School of Medicine. If we are going to think about techniques that foster intervertebral disc regeneration, this is the basic biology we need to understand.

The study appears June 22, 2017, in Current Biology.

Bagnat likens the notochord to a garden hose filled with water. The hardy structure consists of a sheath of epithelial cells surrounding a collection of giant fluid-filled or vacuolated cells. During development, these vacuolated cells rarely pop, despite being under constant mechanical stress. Recent research has suggested that tiny pouches known as caveolae (Latin for little caves) that form in the plasma membrane of these cells can provide a buffer against stretching or swelling.

To see whether the caveolae protected vacuoles from bursting, his team and collaborators from Germany generated mutants of three caveolar genes in their model organism, the zebrafish. Because these small aquarium fish are transparent as embryos, the scientists could easily visualize any spinal defects triggered by the loss of caveolae.

The researchers found that when the mutant embryos hatched and started swimming, exerting pressure on their underdeveloped backbones, their vacuolated cells started to break up. While the finding confirmed their suspicions, it turned up a puzzling discovery. In the caveolar mutants, you see these serial lesions up and down the notochord, and yet the mature spine formed normally, said Bagnat. That was very puzzling to us.

To figure out how that was possible, lead authors Jamie Garcia and Jennifer Bagwell took a closer look at the notochord of mutant fish. They marked the vacuolated cells green and the surrounding epithelial sheath cells red and then filmed the fish shortly after they hatched and started swimming. First, they could see an occasional vacuolated cell break and spill its contents like a water balloon. Then, over the course of fifteen hours, a nearby epithelial sheath cell would move in, crawl over the detritus of the collapsed cell, and morph into a new vacuolated cell.

They performed a few more experiments and found that the repair response was triggered by the release of the cell contents, specifically the basic molecular building blocks known as nucleotides. The researchers then isolated live epithelial sheath cells and treated them with nucleotide analogs to show that they turned into vacuolated cells.

These cells, which reside in the discs of both zebrafish and man, seem capable of controlling their own repair and regeneration, said Bagnat. Perhaps it is a continuous release of nucleotides that is important for keeping the disc in good shape.

The study may offer insight not only into the development of back and neck pain, but also into the origins of cancer. Their data suggests that chordomas, rare and aggressive notochord cell tumors, may begin when epithelial sheath cells leave the notochord and invade the skull and other tissues.

The research was supported by National Institutes of Health (AR065439, AR065439-04S1, T32DK007568-26, and CA193256), a Capes-Humboldt Fellowship, the Max Planck Society, and a Faculty Scholar grant from the Howard Hughes Medical Institute.

CITATION: "Sheath cell invasion and trans-differentiation repair mechanical damage caused by loss of caveolae in the zebrafish notochord," Jamie Garcia, Jennifer Bagwell, Brian Njaine, James Norman, Daniel S. Levic, Susan Wopat, Sara E. Miller, Xiaojing Liu, Jason W. Locasale, Didier Y.R. Stainier and Michel Bagnat. Current Biology, June 22, 2017. DOI# 10.1016/j.cub.2017.05.035

Go here to see the original:
Cells In Fish's Spinal Discs Repair Themselves - Duke Today

Aging-related mutations in blood cells represent major new risk … – Medical Xpress

June 22, 2017 Credit : Susanna M. Hamilton, Broad Communications

Scientists at the Broad Institute of MIT and Harvard have found that a set of genetic mutations in blood cells that arises during aging may be a major new risk factor for cardiovascular disease. In contrast to inherited genetic predispositions and traditional lifestyle risk factors, such as smoking or an unhealthy diet, the new mutations are "somatic mutations" that originate in stem cells in the bone marrow as people age.

Because the mutations are relatively common in older people (over 10% of people over the age of 70 harbor at least one of these mutations), potential future efforts to screen for the mutations in blood cells, identify people at increased risk for coronary heart disease, and reduce risk in those individuals through lifestyle changes or therapeutic interventions could have a significant clinical impact, according to the researchers.

"There is more work to be done, but these results demonstrate that pre-malignant mutations in blood cells are a major cause of cardiovascular disease that in the future may be treatable either with standard therapies or new therapeutic strategies based on these findings," said Benjamin Ebert, a co-senior author of the new study, an institute member at the Broad, a professor of medicine at Harvard Medical School, and a hematologist at Brigham and Women's Hospital.

Featured in the New England Journal of Medicine, the work also contributes to the broader understanding of pathogenesis in coronary heart disease by supporting the hypothesis that inflammation, in addition to elevated cholesterol levels, plays an important role in this illness and potentially other diseases of aging.

"A key finding from this study is that somatic mutations are actually modulating risk for a common disease, something we haven't seen other than in cancer," said first author Siddhartha Jaiswal, a pathologist at Massachusetts General Hospital and researcher in the Ebert lab. "It opens up interesting questions about other diseases of aging in which acquired mutations, in addition to lifestyle and inherited factors, could modulate disease risk."

Previous research led by Ebert and Jaiswal revealed that some somatic mutations that are able to confer a selective advantage to blood stem cells become much more frequent with aging. They named this condition "clonal hematopoiesis of indeterminate potential," (CHIP), and found that it increases the risk of developing a blood cancer more than 10-fold and it appeared to increase mortality from heart attacks or stroke. In the new study, the researchers analyzed data from four case-control studies on more than 8,000 people and found that having one of the CHIP-related mutations nearly doubled the risk for coronary heart disease, with the mutations conferring an even greater risk in people who have previously had a heart attack before age 50.

While the human genetics data showed a strong association between CHIP and coronary heart disease, the team hoped to uncover the underlying biology. Using a mouse model prone to developing atherosclerosis, the scientists showed that loss of one of the CHIP-mutated genes, Tet2, in bone marrow cells leads to larger atherosclerotic plaques in blood vessels, evidence that this mutation can accelerate atherosclerosis in mice.

Atherosclerosis is believed to be a disease of chronic inflammation that can arise in response to excess cholesterol in the vessel wall. To examine this on a cellular level the team turned to the macrophage, an immune cell found in atherosclerotic plaques that can develop from CHIP stem cells and carry the same mutations. Because Tet2 and other CHIP-related mutations are known to be so-called "epigenetic regulators" that can alter the activity of other genes, the team examined gene expression levels in the Tet2-mutated macrophages from mice. They found that the mutated cells appear to be "hyper-inflammatory" with increased expression of inflammatory molecules that contribute to atherosclerosis. In support of this finding, humans with TET2 mutations also had higher levels of one of these molecules, IL-8, in their blood.

The work demonstrates that CHIP associates with coronary heart disease in humans, that mutation of the CHIP-related gene Tet2 causes atherosclerosis in mice, and that an inflammatory mechanism likely underlies the process. More work is needed to show whether other genes that are mutated in CHIP also lead to increased inflammation. The team is also exploring whether interventions such as cholesterol lowering therapy or anti-inflammatory drugs might have benefit in people with CHIP.

Inflammation is also thought to modulate several other diseases of aging besides cardiovascular disease, such as autoimmune disorders and neurodegenerative disease. Because CHIP also increases in frequency with age, somatic mutations that alter inflammatory processes could influence several diseases of aging, though more work is needed to test this possibility.

"By combining genetic analysis on large cohorts with disease model and gene expression studies, we've been able to confirm the earlier hints of CHIP's surprising role in cardiovascular disease," said co-senior author Sekar Kathiresan, director of the Broad's Cardiovascular Disease Initiative, associate professor of medicine at Harvard Medical School, and director of the Center for Genomic Medicine at Massachusetts General Hospital. "Beyond the mutations that you inherit from your parents, this work reveals a new genetic mechanism for atherosclerosismutations in blood stem cells that arise with aging."

Explore further: A role for mutated blood cells in heart disease?

More information: Siddhartha Jaiswal et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, New England Journal of Medicine (2017). DOI: 10.1056/NEJMoa1701719

A new study provides some of the first links between relatively common mutations in the blood cells of elderly humans and atherosclerosis.

A significant percentage of lymphoma patients undergoing transplants with their own blood stem cells carry acquired genetic mutations that increase their risks of developing second hematologic cancers and dying from other ...

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers have found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.

A new strategy - an injectable antibody - for lowering blood lipids and thereby potentially preventing coronary artery disease and other conditions caused by the build-up of fats, cholesterol, and other substances on the ...

Natural genetic changes can put some people at high risk of certain conditions, such as breast cancer, Alzheimer's disease or high blood pressure. But in rare cases, genetic errors also can have the opposite effect, protecting ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Aging-related mutations in blood cells represent major new risk ... - Medical Xpress

Sweden Launches Initiative to Establish Center for Cell and Gene Therapy Research – Genetic Engineering & Biotechnology News

Sweden aims to establish a new Center for Advanced Medical Products (CAMP) as part of a SEK 320-million ($36.6-million), 8-year Swedish government initiative to position the country as a leading biologics developer.

Swedish regenerative medicine firm Xintela has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy research center, with SEK 48 million ($5.5 million) in funding from the countrys innovation agency and research council, Vinnova and Vetenskapsrdet. Xintel said that as one of the CAMP initiative founders, it will work with Swedens universities, research institutes, and with firms including AstraZeneca, GE Healthcare and Pfizer. Xintela will initially act as an advisor for development of the center, but in the longer term expects to benefit from emerging R&D.

It is gratifying that the Swedish government, Vinnova and Vetenskapsrdet acknowledge the huge potential of cell and gene therapy and the strong position that Sweden has in this research field,commented Xintela CEO Evy Lundgren-kerlund. Xintela is one of the companies in Sweden with large development potential in cell therapy, which makes us a natural partner for this project.

In the short term CAMP aims to establish itself as an internationally recognised center for R&D, innovation and clinical practice, and to promote industrial growth and SMEs. Longer-term goals include attracting investment from the global pharmaceutical and biotech sectors.

Xintela is exploiting its XINMARK protein marker technology and XACT (Xintela assay for cell therapy) assay platform to develop an allogeneic mesenchymal stem cell-based therapy for repairing cartilage damage in osteoarthritis, and to progress a tumor-targeting antibody treatment for glioblastoma.

Last month the firm established a collaboration with Germany-based CO.DON, which develops autologous cell therapies for cartilage repair. The firms will work together on the development of Xintelas markers both for a next generation CO.DN cell therapy program and for Xintelas cartilage repair cell therapy product.

Here is the original post:
Sweden Launches Initiative to Establish Center for Cell and Gene Therapy Research - Genetic Engineering & Biotechnology News

ICT halts Ph III brain cancer cell therapy trial due to lack of cash – BioPharma-Reporter.com

ImmunoCellular Therapeutics Ltd has halted a Phase III trial of its brain cancer cell therapy ICT-107 due to a lack of funds and is looking for a buyer or partner for the programme.

The Los Angeles, US-based biotech announced the move on June 21, explaining it is unable at this time to secure sufficient additional financial resources to complete the phase III registration trial of ICT-107.

ImmunoCellular said it is looking for a partner or buyer for the programme adding that the suspension of the phase III registration trial of ICT-107 is expected to reduce the amount of cash used in the Companys operations.

ICT-107 is a dendritic cell (DC) vaccine designed to activate a patients immune system to target six different antigens associated with glioblastoma multiforme, a form of brain cancer.

ThePhase III trial is being conducted at sites in the US, Austria and Canada.

The halt comes weeks after ImmunoCellular Therapeutics signalled its intention to raise funds to allow it to continue the study.

R&D costs

According to a first quarter filing ,ImmunoCellular Therapeutics has cash reserves of $5.3m (4.68m), which is just under half of what it had in reserve this time last year.

The document also revealed the firm spent $5.4m in the quarter, the majority of which was used for R&D.

Supplies of ICT-107 for the trial were produced by Netherlands-based contractor PharmaCell, under an agreement announced in 2015 , andCaladrius subsidiary PCT under an deal signed the same year.

Financial details of the contracts have not been disclosed, althoughImmunoCellular Therapeutics does state in its Q1 filing that it is paying PharmaCell for "manufacturing services."

Similarly, while ImmunoCellular Therapeutics does not provide specifics about itsdeal withPCT, it does is say the contractoris providing manufacturing services for the Phase III ICT-107 trial and for a Phase 1 study of ICT-121, a second cell therapy candidate.

ImmunoCellular Therapeutics is alsopaying PCT monthly fees for the use of a controlled environment room and personnel performing the services.

PharmaCell was acquired by Swiss life sciences supplier Lonza last week .

Read the original post:
ICT halts Ph III brain cancer cell therapy trial due to lack of cash - BioPharma-Reporter.com

Dr Prathap C Reddy: Dr Prathap Reddy on the advantages of cell … – ETHealthworld.com

By Rajesh Barnwal

Apollo Hospitals and RMS REGROW on Monday announced their partnership to offer two new Regenerative Medicine Cell Therapy products -- Ossron and Chondron for bone and cartilage problems, respectively to patients in India. According to RMS REGROW, which claims to be the first Make in India company in Cell Therapy Technology, both the products have received the necessary approval from the Drug Controller General of India (DCGI) and have already been tested on 150 patients, none of whom showed any adverse reaction.

On the sidelines of the occasion, ETHealthworld caught up with Dr Prathap C Reddy, founder-chairman of Apollo Hospitals, to find out more about the new technology. An edited excerpt:

Whats the objective that you seek to achieve through this partnership?

I think one is pride. REGROW has made a product in India, got it certified by DCGI, and given to the people. But the certification is not ordinary. They had to go through tremendous regulatory procedures to find that it is safe. And we know well because we participated in the trial. We know that its a safe and effective product both in the management of cartilage damage as well as osteoporosis. So, I think its a great compliment for REGROW and we are happy Apollo is associated with this and we are going to take it to at least 50 of our hospitals to start with. Its going to be a tremendous advantage for the people because if you want the same thing anywhere in the world it would cost approximately 10-20 times more.

How many patients do you see getting benefits from this technology in the next one year?

I think there is no statistics unfortunately for the people who suffer from the minimal or moderate knee pain. They dont go to a doctor or a hospital and swallow pain killer or anti-inflammatory thing and get along with the work. But sometimes it is troublesome; so, if they come to a doctor and say they realise the injury is minimal or moderate this cell therapy is the best thing. All they (doctors) do is they look at through an arthroscope and see whether the cartilage is damaged. If the cartilage is damaged they will demonstrate it to you how simple it is to take a sample from that and grow the same cells in the lab. It (cell therapy) is not like stem cells. Stem cells would neutralise it to make it what we want out of it. If you want to make bone, it would make bone; if you want to make neuro cell, it would make neuro cell; if you want to make blood cell, it would make blood cell out of that stem cell. But here we are making the same thing, cartilage cell is multiplied and bone cell for arthroplasty is multiplied. I think its a tremendous advantage. The process has been made wonderfully well.

This is certainly a new trend. What other new trends you see in the healthcare sector?

I am one of those who feel from day one, 34 years ago when I got into Apollo saying that we, as Indians, deserve the same thing that anybody else got in the world. So, I started a hospital. We are doing everything thats possible, starting from a bypass surgery, because I am a cardiologist. Today we have done the largest number of transplants -- heart transplants, heart-lung transplants, liver, kidney, pancreatic transplants, intestinal transplants, in all of these we became number one in the world; we overtook the largest centre in the US two years ago.

I think the number is not that important in healthcare; in healthcare, whats most important is what is the safety, whats the outcome, and then naturally for the individual what does it cost? I think we have given the same or better outcomes than the best centres in the world at a fraction of the cost. You take bypass, which costs 100,000 dollars, we charge 2,500 dollars. Kidney transplant procedure, which costs something like one crore rupees, we are doing it for 25 lakh rupees. Now, I am getting Proton (Proton Therapy for Cancer Treatment), which is not available in UK, not available in Australia, in Singapore, Malaysia, Middle East or Africa -- three billion people dont have it. This Proton Therapy System is going to cost me about Rs 900 crore; it has arrived in Chennai and its installation is going on; hopefully, they will give it to me in a years time. Then I will be able to give this to people who dont have to travel abroad and spend one and half or two crores of rupees for the treatment. And mostly it is for children. Philanthropically I am trying to build a trust to treat some poor children.

You mentioned that the new cell therapy treatment would cost about Rs 3-4 lakh. Whats the cost of a typical knee replacement surgery?

A knee replacement would cost somewhere around Rs 8-10 lakh in India. What I compliment not only Apollo but all the good hospitals in India for giving the same outcome at a 10 percent of the international cost.

So apart from affordability, what are the other advantages of this new technology?

The great advantage is that people with minimal or moderate pain, instead of swallowing pills, they can get this done simply and become normal. Thats the advantage.

More here:
Dr Prathap C Reddy: Dr Prathap Reddy on the advantages of cell ... - ETHealthworld.com

Patient with severe burns treated using stem cell therapy – Business Standard

IANS | Mumbai June 23, 2017 Last Updated at 00:16 IST

Raising hopes of new and less painful treatment for burn injuries, a 26-year-old patient with Grade 2 burn injuries was successfully treated using stem cell therapy at a city-based hospital, doctors said on Thursday.

Anand Tiwari suffered burns after accidentally falling in a boiler unit while at work. He sustained Grade 2 and early Grade 3 burns in all parts of the body below his neck.

When admitted to the city based StemRx Bioscience Solutions hospital, he had severe burning sensation and pain all over the body. Blisters and swellings were noticed in many areas of his chest and limbs.

According to doctors, after initial care and stabilisation of the patient, for treatment of burns, a treatment protocol was prepared by Pradeep Mahajan, a regenerative medicine researcher at Stemrx Bioscience Solutions Hospital.

Explaining the treatment procedure, Mahajan said: "This involved the use of growth factors and fibroblasts and collagen based gel. These biological agents stimulate natural healing mechanisms in the body."

"The advantage of these growth factors is that they can be obtained from the patients' own body and hence are safe and effective. Additionally, unlike conventional treatment options, biological agents promote faster recovery," he said.

Under the stem cell therapy, the treatment process has to be repeated continuously so as to get rid of the problem completely and accordingly the procedure was performed.

"During the entire treatment, the patient was not given any closed dressing. He also underwent blood and supplementary fluid transfusion as required to maintain systemic homeostasis," said Mahajan.

He said that changes in the patient were observed as early as two-three days after the initiation of therapy. Drying of superficial burns began and swelling started reducing.

"Gradually, dry crusts started peeling and by the end of the third week, initial healing of most areas was complete. There was no odour or oozing from any wound and he did not complain of pain or burning sensation anymore.

"After a month-long treatment, healthy skin formation is being observed and further healing is progressing at an impressive rate," said Mahajan, adding that in treatment through conventional modalities, it takes more than eight weeks for healing to happen and further several months for patient to be able to regain joint and facial movements.

--IANS

rup/nir

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Raising hopes of new and less painful treatment for burn injuries, a 26-year-old patient with Grade 2 burn injuries was successfully treated using stem cell therapy at a city-based hospital, doctors said on Thursday.

Anand Tiwari suffered burns after accidentally falling in a boiler unit while at work. He sustained Grade 2 and early Grade 3 burns in all parts of the body below his neck.

When admitted to the city based StemRx Bioscience Solutions hospital, he had severe burning sensation and pain all over the body. Blisters and swellings were noticed in many areas of his chest and limbs.

According to doctors, after initial care and stabilisation of the patient, for treatment of burns, a treatment protocol was prepared by Pradeep Mahajan, a regenerative medicine researcher at Stemrx Bioscience Solutions Hospital.

Explaining the treatment procedure, Mahajan said: "This involved the use of growth factors and fibroblasts and collagen based gel. These biological agents stimulate natural healing mechanisms in the body."

"The advantage of these growth factors is that they can be obtained from the patients' own body and hence are safe and effective. Additionally, unlike conventional treatment options, biological agents promote faster recovery," he said.

Under the stem cell therapy, the treatment process has to be repeated continuously so as to get rid of the problem completely and accordingly the procedure was performed.

"During the entire treatment, the patient was not given any closed dressing. He also underwent blood and supplementary fluid transfusion as required to maintain systemic homeostasis," said Mahajan.

He said that changes in the patient were observed as early as two-three days after the initiation of therapy. Drying of superficial burns began and swelling started reducing.

"Gradually, dry crusts started peeling and by the end of the third week, initial healing of most areas was complete. There was no odour or oozing from any wound and he did not complain of pain or burning sensation anymore.

"After a month-long treatment, healthy skin formation is being observed and further healing is progressing at an impressive rate," said Mahajan, adding that in treatment through conventional modalities, it takes more than eight weeks for healing to happen and further several months for patient to be able to regain joint and facial movements.

--IANS

rup/nir

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

IANS

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

More here:
Patient with severe burns treated using stem cell therapy - Business Standard

Former Titan Tim Shaw visits Bowling Green for book signing – Bowling Green Daily News

KYZ023>043-045>049-053>057-061>067-070>078-081-082-230900-/O.NEW.KLMK.FF.A.0009.170623T1500Z-170624T1200Z//00000.0.ER.000000T0000Z.000000T0000Z.000000T0000Z.OO/Hancock-Breckinridge-Meade-Ohio-Grayson-Hardin-Bullitt-Jefferson-Oldham-Trimble-Henry-Shelby-Franklin-Scott-Harrison-Spencer-Anderson-Woodford-Fayette-Bourbon-Nicholas-Nelson-Washington-Mercer-Jessamine-Clark-Larue-Marion-Boyle-Garrard-Madison-Butler-Edmonson-Hart-Green-Taylor-Casey-Lincoln-Logan-Warren-Simpson-Allen-Barren-Monroe-Metcalfe-Adair-Russell-Cumberland-Clinton-Including the cities of Lewisport, Hawesville, Hardinsburg, Brandenburg, Hartford, Leitchfield, Elizabethtown, Shepherdsville, Louisville, La Grange, Bedford, Milton, New Castle, Shelbyville, Frankfort, Georgetown, Cynthiana, Taylorsville, Lawrenceburg, Versailles, Lexington, Paris, Carlisle, Bardstown, Springfield, Harrodsburg, Nicholasville, Winchester, Hodgenville, Lebanon, Danville, Lancaster, Richmond, Morgantown, Brownsville, Horse Cave, Greensburg, Campbellsville, Liberty, Stanford, Russellville, Bowling Green, Franklin, Providence, Scottsville, Glasgow, Tompkinsville, Edmonton, Columbia, Jamestown, Burkesville, and Albany118 PM EDT Thu Jun 22 2017 /1218 PM CDT Thu Jun 22 2017/...FLASH FLOOD WATCH IN EFFECT FROM FRIDAY MORNING THROUGH EARLYSATURDAY MORNING...The National Weather Service in Louisville has issued a* Flash Flood Watch for central Kentucky. * From Friday morning through early Saturday morning* A cold front coming in from the northwest will join forces with the remnants of Tropical Storm Cindy to produce widespread rain, possibly heavy.PRECAUTIONARY/PREPAREDNESS ACTIONS...A Flash Flood Watch means that conditions may develop that leadto flash flooding. Flash flooding is a very dangerous situation.You should monitor later forecasts and be prepared to take actionshould Flash Flood Warnings be issued.&&$$

Visit link:
Former Titan Tim Shaw visits Bowling Green for book signing - Bowling Green Daily News

What is sickle cell disease? – Popular Science

On Wednesday, rapper Albert Johnsonbetter known by his stage name Prodigypassed away at the age of 42 from complications of sickle cell disease, an inherited blood disorder he'd had since birth. Though some medications can help those with sickle cell manage their condition, no cure or real treatment exists to combat the disease. And while better care in the United States has extended the lifespan of those with the disease, they often face a lifelong battle with pain, infections, and extreme fatigue.

Sickle cell disease afflicts millions of people worldwide; in the United States alone, about 100,000 live with the blood condition. Someone born with sickle cell disease could only expect to live an average of 14 years in the 1970s, and today the average lifespan still only hits 40 to 50 years.

Sickle cell disease is a term for a group of inherited blood disorders that affect the shape of a persons hemoglobinthe protein found in red blood cells that carries and delivers oxygen to the rest of the body.

In genetic terms, the disease is autosomal recessive. For a person to develop it, they must receive two different abnormal hemoglobin genes, one from their mother and one from their father. A few different types of these abnormal genes exist, but for it to develop into sickle cell disease, one of these irregular genes must be a type called hemoglobin S. If a person receives two hemoglobin S genes, then they develop whats called sickle cell anemia, which is the most common and serious disease in the group.

The disease is so debilitating because hemoglobin is one of the most important proteins in the body. When blood reaches the lungs, its job is to collect and transport oxygen to the rest of your organs, which is crucial for survival. Hemoglobin travels inside red blood cells. These cells are typically disc shaped, a form that allows them to easily maneuver en masse through the narrow twists and turns of blood vessels as they travel through the body. But hemoglobin S is weirdly rod shaped, and because of its large size relative to red blood cells, it forces them to take on this oblong shape as well. When every red blood cell is shaped this way, a bunch of them can get jammed inside a blood vessel, slowing or stopping blood flow and preventing oxygen from getting to vital organs. This lack of oxygen can trigger severe pain throughout the body and causes whats known as a pain crisis, the most common debilitating side effect of the disease. While some people dont experience much pain, if any, in between these episodes, others live with chronic, ongoing pain throughout their lives. Meanwhile, while a healthy body constantly replenishes its red blood cells, sickle shaped red blood cells tend to die more easily and people with sickle cell disease often arent able to keep up with this loss. A lack of red blood cells, known as anemia, can lead to crippling fatigue.

In the United States, and around the world, the disease is more common in people of African descent. One of the main reasons for this is because people with sickle cell disease, and those with just one copy of the sickle cell trait, have a better chance at surviving malaria, which is common in Africa, than those without the trait. While the exact mechanism of this is not completely clear, researchers do know that because the microorganisms that cause malaria reside in red blood cells, the frequent destruction of sickled red blood cells forces the microorganisms out as well. Sickle cell is a textbook example of an evolutionary phenomenon called balancing selection: genes that can cause sickle cell in pairs are much more likely to persist in populations that get some benefit out of a single copy of the genewhich is only the case in regions plagued by malaria. Within those regions, the benefit of one copy of the gene keeps it from being selected out of the population; the devastating effects of two copies of the gene keep it from becoming too commonplace.

There is currently no cure for the disease. People are often given pain medications and blood transfusions to manage the pain crises and lack of oxygen, but theres no way to stop the body from making these poorly-shaped hemoglobin cells.

Some people have tried stem cell transplants, where doctors kill off the abnormal hemoglobin with drugs before infusing patients with blood cells from a donor's bone marrow. Finding a suitable donor is tricky though, and these transplants are especially risky for adults.

However, future treatments may be on the horizon. Because sickle cell disease arises from a mutation in a single gene in a persons DNA, new gene editing technologies such as CRISPR-Cas9, which allows scientists to edit the human genome with relative ease, could perhaps lead to a way to cure the disease. In fact, this past year, researchers at the University of California, Berkeley, published results from a study showing success in using CRISPR to edit out the disease in mice. However, while promising, we're still a long way from the treatment reaching humans. The biggest concern is that the editing technique will alter other areas of the genome that appear similar to the ones that need to be edited outsomething called off-target effects. Researchers still need to understand why these off-target effects occur, and how to prevent them, before this technique can be safely used in humans.

Read more from the original source:
What is sickle cell disease? - Popular Science